OBJECTIVES: Trends in lung cancer surgery may reveal potential for improvement and are important for planning by care providers. METHODS: Using data from the Cancer Registry of Norway, we analysed the outcomes of lung cancer surgery during the periods of 1994-95, 2000-01 and 2006-07. The Cox regression model was carried out to identify the period effect on survival. RESULTS: A total of 2201 patients were operated on. Surgery was centralized from 24 hospitals in the first two periods to 13 hospitals in the last. The resection rates varied from 6 to 31% across the counties. From the first to the last period, the national resection rate increased from 16 to 19% (P(trend) = 0.001), and the 1-year survival rate increased from 73 to 82%. The proportion of resected patients in pathological stage I-II decreased from 87 to 83% (P(trend) = 0.048), the proportion of pneumonectomies from 27 to 15% (P(trend)<0.001), and the rate of mortality within 30 days of the surgery from 4.8 to 3.0% (P(trend) = 0.072). In the first two periods, 31% of these early deaths were caused by complications directly related to the surgical technique, whereas, in the latter period, no deaths were directly related. The only unfavourable trend was the waiting time between the final diagnostic procedure and surgery, which increased from 29 to 40 days throughout the three periods (P < 0.001). Survival (excluding those who died within 30 days) was significantly improved in the last period (risk ratio (RR): 0.72 (P < 0.001)). CONCLUSIONS: Despite an increased surgical waiting time, important aspects of lung cancer surgery, including resection rates, have improved in recent years.
OBJECTIVES: Trends in lung cancer surgery may reveal potential for improvement and are important for planning by care providers. METHODS: Using data from the Cancer Registry of Norway, we analysed the outcomes of lung cancer surgery during the periods of 1994-95, 2000-01 and 2006-07. The Cox regression model was carried out to identify the period effect on survival. RESULTS: A total of 2201 patients were operated on. Surgery was centralized from 24 hospitals in the first two periods to 13 hospitals in the last. The resection rates varied from 6 to 31% across the counties. From the first to the last period, the national resection rate increased from 16 to 19% (P(trend) = 0.001), and the 1-year survival rate increased from 73 to 82%. The proportion of resected patients in pathological stage I-II decreased from 87 to 83% (P(trend) = 0.048), the proportion of pneumonectomies from 27 to 15% (P(trend)<0.001), and the rate of mortality within 30 days of the surgery from 4.8 to 3.0% (P(trend) = 0.072). In the first two periods, 31% of these early deaths were caused by complications directly related to the surgical technique, whereas, in the latter period, no deaths were directly related. The only unfavourable trend was the waiting time between the final diagnostic procedure and surgery, which increased from 29 to 40 days throughout the three periods (P < 0.001). Survival (excluding those who died within 30 days) was significantly improved in the last period (risk ratio (RR): 0.72 (P < 0.001)). CONCLUSIONS: Despite an increased surgical waiting time, important aspects of lung cancer surgery, including resection rates, have improved in recent years.
Authors: Tao Lu; Xiaodong Yang; Yiwei Huang; Mengnan Zhao; Ming Li; Ke Ma; Jiacheng Yin; Cheng Zhan; Qun Wang Journal: Cancer Manag Res Date: 2019-01-21 Impact factor: 3.989
Authors: Samina Park; In Kyu Park; Eung Re Kim; Yoohwa Hwang; Hyun Joo Lee; Chang Hyun Kang; Young Tae Kim Journal: Cancer Res Treat Date: 2016-07-18 Impact factor: 4.679
Authors: Anna Rich; David Baldwin; Inmaculada Alfageme; Paul Beckett; Thierry Berghmans; Stephen Brincat; Otto Burghuber; Alexandru Corlateanu; Tanja Cufer; Ronald Damhuis; Edvardas Danila; Joanna Domagala-Kulawik; Stefano Elia; Mina Gaga; Tuncay Goksel; Bogdan Grigoriu; Gunnar Hillerdal; Rudolf Maria Huber; Erik Jakobsen; Steinn Jonsson; Dragana Jovanovic; Elena Kavcova; Assia Konsoulova; Tanel Laisaar; Riitta Makitaro; Bakir Mehic; Robert Milroy; Judit Moldvay; Ross Morgan; Milda Nanushi; Marianne Paesmans; Paul Martin Putora; Miroslav Samarzija; Arnaud Scherpereel; Marc Schlesser; Jean-Paul Sculier; Jana Skrickova; Renato Sotto-Mayor; Trond-Eirik Strand; Paul Van Schil; Torsten-Gerriet Blum Journal: BMC Cancer Date: 2018-11-20 Impact factor: 4.430